1. N100 as a response prediction biomarker for accelerated 1 Hz right DLPFC-rTMS in major depression.
- Author
-
Sheen JZ, Mazza F, Momi D, Miron JP, Mansouri F, Russell T, Zhou R, Hyde M, Fox L, Voetterl H, Assi EB, Daskalakis ZJ, Blumberger DM, Griffiths JD, and Downar J
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Treatment Outcome, Biomarkers, Prefrontal Cortex physiopathology, Depressive Disorder, Major therapy, Depressive Disorder, Major physiopathology, Transcranial Magnetic Stimulation methods, Electroencephalography, Evoked Potentials physiology, Dorsolateral Prefrontal Cortex physiology
- Abstract
Background and Objective: Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for major depressive disorder (MDD); however, this treatment currently lacks reliable biomarkers of treatment response. TMS-evoked potentials (TEPs), measured using TMS-electroencephalography (TMS-EEG), have been suggested as potential biomarker candidates, with the N100 peak being one of the most promising. This study investigated the association between baseline N100 amplitude and 1 Hz right dorsolateral prefrontal cortex (R-DLPFC) accelerated rTMS (arTMS) treatment in MDD., Methods: Baseline TMS-EEG sessions were performed for 23 MDD patients. All patients then underwent 40 sessions of 1 Hz R-DLPFC (F4) arTMS over 5 days and a follow-up TMS-EEG session one week after the end of theses arTMS sessions., Results: Baseline N100 amplitude at F4 showed a strong positive association (p < .001) with treatment outcome. The association between the change in N100 amplitude (baseline to follow-up) and treatment outcome did not remain significant after Bonferroni correction (p = .06, corrected; p = .03, uncorrected). Furthermore, treatment responders had a significantly larger mean baseline F4 TEP amplitude during the N100 time frame compared to non-responders (p < .001). Topographically, after Bonferroni correction, F4 is the only electrode at which its baseline N100 amplitude showed a significant positive association (p < .001) with treatment outcome., Limitations: Lack of control group and auditory masking., Conclusion: Baseline N100 amplitude showed a strong association with treatment outcome and thus demonstrated great potential to be utilized as a cost-effective and widely adoptable biomarker of rTMS treatment in MDD., Competing Interests: Declaration of competing interest JZS, FMazza, DM, FMansouri, TR, RZ, MH, LF, HV, EBA do not report any conflict of interest. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. ZJD has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work has been supported by the Canadian Institutes of Health Research (CIHR), the National Institute of Mental Health (NIMH), Brain Canada and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. JD has received research support from the Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions, holds equity in Arc Health Partners, and is a co-founder of Ampa. JPM reports research support from the Brain & Behavior Research Foundation (BBRF), the Réseau Québécois sur le Suicide, les troubles de l'Humeur et les troubles Associés (RQSHA), the Canadian Research Initiative in Substance Misuse (CRISM), the Fonds de Recherche du Québec - Santé (FRQS), the Branch Out Neurological Foundation, and the Canadian Institutes of Health Research (CIHR). JDG has received research support from the Labatt Family Network, the CAMH Discovery Fund, the University of Toronto EMHSeed program, and the Tri-Council Canada-UK AI Initiative., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF